TrialReader


AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

NCT00519233 — Phase 1, Completed, 13 participants, Astellas Pharma Inc

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

RegistryNCT00519233
StatusCompleted
PhasePhase 1
Study typeInterventional; non randomized, single group, masking: none, treatment
Enrollment13 (Actual)
SponsorAstellas Pharma Inc (Industry); collaborators: Agensys, Inc.
ConditionsProstate Cancer
InterventionsAGS-1C4D4 (Drug)
Datesstart 2007-09-01, primary completion 2009-09-01, completion 2009-09-01, first posted 2007-08-22, last updated 2014-05-02
Locations2 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Prostate Cancer All trials of AGS-1C4D4

-Summary

The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.

Expand all sections  ·  Collapse all

+Detailed description

Cohorts of 1-6 patients will be administered AGS-1C404 in sequentially rising dose levels. Dose escalation will continue until the MTD of AGS-1C4D4 is established or the maximum planned dose is reached.

+Arms and interventions

ArmTypeInterventionsDescription
1.AGS-1C4D4ExperimentalDrug: AGS-1C4D4
  • AGS-1C4D4 (Drug): IV

+Outcome measures

Primary outcomes

  • Safety, tolerability and side effects of AGS-1C4D4 in adult patients with advanced HRPC. [3 Months]

Secondary outcomes

  • The pharmacokinetic profile of AGS-1C4D4 in adult patients with advanced HRPC. [3 Months]

+Eligibility

Sex: Male, ages: 18 Years to any

Inclusion Criteria:

* Patient has hormone-refractory metastatic prostate cancer

Exclusion Criteria:

* Patient has had chemotherapy, radiotherapy, or biological therapy within the past 4 weeks or has not recovered from side effects
* Patient is currently participating or has participated in an investigational study within the past 30 days
* Patient has illness or circumstance that could limit compliance with the study requirements
* Patient uses illicit drugs or had a recent history of drug or alcohol abuse within the last year
* Patient has Hepatitis B or C

+Locations (2)

FacilityCityCountryStatus
Baltimore, MarylandUnited States
New York, New YorkUnited States

+Publications

  • Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. doi: 10.1007/s00280-011-1759-9. Epub 2011 Oct 22. PMID 22020316

+Investigators

  • Central Contact, Study director, Agensys, Inc.

My Notes